The REVEAL study
REVEAL 研究
基本信息
- 批准号:8552344
- 负责人:
- 金额:$ 4.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute myocardial infarctionAnimal ModelApoptosisCD34 geneCardiacCardiovascular systemCause of DeathCell CountCellsCessation of lifeConfidence IntervalsCryopreservationDoseDouble-Blind MethodEnrollmentEpoetin AlfaErythropoietinEventExperimental ModelsHourInfarctionInjuryInterventionIntravenousIntravenous BolusIschemiaLeft Ventricular FunctionLeft Ventricular MassLeft Ventricular RemodelingMagnetic ResonanceMagnetic Resonance ImagingMeasuresMethodsMononuclearMorbidity - disease rateMulticenter TrialsMyocardial InfarctionOutcomeOutcome MeasureParticipantPatientsPharmaceutical PreparationsPhasePlacebo ControlPlacebosProcessRandomizedReperfusion TherapySafetySalineSamplingScanningSiteStem cellsStentsStrokeSubgroupThrombosisTimeVentricular Remodelingagedaldehyde dehydrogenasescohortdesignfollow-upimprovedindexingmortalityneovascularizationolder patientpercutaneous coronary interventionprospectivetrend
项目摘要
Context: Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause
of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct
size and improves left ventricular (LV) function.
Objective: To evaluate the safety and efficacy of a single intravenous bolus of epoetin
alfa in patients with STEMI.
Design, Setting, and Patients: A prospective, randomized, double-blind, placebocontrolled
trial with a dose-escalation safety phase and a single dose (60 000 U of epoetin
alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling
With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted
at 28 US sites between October 2006 and February 2010, and included 222 patients
with STEMI who underwent successful percutaneous coronary intervention (PCI) as a
primary or rescue reperfusion strategy.
Intervention: Participants were randomly assigned to treatment with intravenous epoetin
alfa or matching saline placebo administered within 4 hours of reperfusion.
Main Outcome Measure: Infarct size, expressed as percentage of LV mass, assessed
by cardiac magnetic resonance (CMR) imaging performed 2 to 6 days after study
medication administration (first CMR) and again 122 weeks later (second CMR).
Results In the efficacy cohort, the infarct size did not differ between groups on either
the first CMR scan (n=136; 15.8% LV mass 95% confidence interval CI, 13.3-
18.2% LV mass for the epoetin alfa group vs 15.0% LV mass 95% CI, 12.6-17.3%
LV mass for the placebo group; P=.67) or on the second CMR scan (n=124; 10.6%
LV mass 95% CI, 8.4-12.8% LV mass vs 10.4% LV mass 95% CI, 8.5-12.3% LV
mass, respectively; P=.89). In a prespecified analysis of patients aged 70 years or older
(n=21), the mean infarct size within the first week (first CMR) was larger in the epoetin
alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV mass) than in the placebo
group (11.7% LV mass; 95% CI, 7.2-16.1% LV mass) (P=.03). In the safety cohort,
of the 125 patients who received epoetin alfa, the composite outcome of death, MI,
stroke, or stent thrombosis occurred in 5 (4.0%; 95% CI, 1.31%-9.09%) but in none
of the 97 who received placebo (P=.04).
Conclusions: In patients withSTEMIwhohad successful reperfusion with primary or rescue
PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct
size and was associated with higher rates of adverse cardiovascular events. Subgroup
analyses raised concerns about an increase in infarct size among older patients.
In a follow-up study, we aimed to determine the feasibility of centrally analyzing EPCs levels to assess the relationship between EPC levels, and EPO administration and infarct size.
Methods: Mononuclear cells (MNCs) were locally cryopreserved for central processing from samples obtained prior to rescue or primary percutaneous coronary intervention, as well as at 24 h and 48C72 h postintervention, and analyzed for cells expressing CD133, CD34, and aldehyde dehydrogenase activity.
Results: Sampling of EPCs was attempted in 163 of 222 enrolled patients. At least one analyzable sample was obtained in 125 patients, and all three time points were available in 83 patients. There were no statistically significant differences in EPC numbers over time or in the absolute EPC levels between EPO- and placebo-treated patients. There was a trend toward a greater increase in EPC levels from 24 h postintervention to 48C72 h postintervention in patients receiving 30 000 U of EPO ( = 0.11 (placebo) vs 0.092 (EPO), p=0.05). EPC numbers at baseline were inversely related to infarct size (p=0.006, r=-0.39).
Conclusions: Local whole cell cryopreservation and central EPC analysis is possible. High-dose (30 000 U) EPO may mobilize EPCs at 48C72 h. Baseline EPC levels are inversely associated with infarct size, suggesting that acute EPC mobilization may be a viable strategy to minimize acute injury.
背景:急性 ST 段抬高型心肌梗死 (STEMI) 是一个主要原因
发病率和死亡率。在 MI 实验模型中,促红细胞生成素可减少梗塞
大小并改善左心室(LV)功能。
目的:评价单次静脉推注促红细胞生成素的安全性和有效性
STEMI 患者服用阿尔法。
设计、环境和患者:前瞻性、随机、双盲、安慰剂对照
剂量递增安全阶段和单剂量(60 000 U 促红细胞生成素
alfa)功效期;减少梗塞扩张和心室重塑
进行大面积心肌梗死后促红细胞生成素 (REVEAL) 试验
2006 年 10 月至 2010 年 2 月期间在美国 28 个地点进行,包括 222 名患者
患有 STEMI 并成功接受经皮冠状动脉介入治疗 (PCI) 的患者
主要或救援再灌注策略。
干预:参与者被随机分配接受静脉注射促红细胞生成素治疗
再灌注后 4 小时内给予 alfa 或匹配的生理盐水安慰剂。
主要结果指标:评估梗死面积,以左心室质量的百分比表示
通过研究后 2 至 6 天进行的心脏磁共振 (CMR) 成像
药物给药(第一次 CMR),122 周后再次给药(第二次 CMR)。
结果 在疗效队列中,两组之间的梗死面积没有差异
第一次 CMR 扫描(n=136;15.8% LV 质量 95% 置信区间 CI,13.3-
阿尔法促红细胞生成素组 LV 质量为 18.2% vs LV 质量 15.0% 95% CI, 12.6-17.3%
安慰剂组的 LV 质量; P=.67) 或第二次 CMR 扫描 (n=124; 10.6%
左室质量 95% CI,8.4-12.8% 左室质量 vs 10.4% 左室质量 95% CI,8.5-12.3% 左室
质量,分别; P=.89)。在对 70 岁或以上患者的预先指定分析中
(n=21),第一周内的平均梗死面积(第一次 CMR)在促红细胞生成素中更大
alfa 组(19.9% LV 质量;95% CI,14.0-25.7% LV 质量)高于安慰剂组
组(11.7% LV 质量;95% CI,7.2-16.1% LV 质量)(P=.03)。在安全队列中,
在接受阿法依泊汀治疗的 125 名患者中,死亡、心肌梗死、
5 例发生中风或支架内血栓(4.0%;95% CI,1.31%-9.09%),但没有发生
97 名接受安慰剂的人中的 (P=.04)。
结论:在初次或抢救成功再灌注的 STEMI 患者中
PCI(PCI 后 4 小时内单次静脉推注阿法红细胞生成素并不能减少梗塞)
大小,并与较高的不良心血管事件发生率相关。子群
分析引起了人们对老年患者梗塞面积增加的担忧。
在后续研究中,我们旨在确定集中分析 EPC 水平以评估 EPC 水平、EPO 给药和梗塞面积之间关系的可行性。
方法:对抢救或初次经皮冠状动脉介入治疗前以及干预后 24 小时和 48°C72 小时获得的样本进行局部冷冻保存,以便进行中央处理,并分析表达 CD133、CD34 和乙醛脱氢酶活性的细胞。
结果:尝试对 222 名入组患者中的 163 名进行 EPC 采样。 125 名患者至少获得了一份可分析样本,83 名患者的所有三个时间点均可用。 EPO 和安慰剂治疗患者之间的 EPC 数量随时间变化或绝对 EPC 水平没有统计学上的显着差异。在接受 30 000 U EPO 的患者中,从干预后 24 小时到干预后 48°C72 小时,EPC 水平有更大增加的趋势(= 0.11(安慰剂)与 0.092(EPO),p=0.05)。基线时的 EPC 数量与梗塞面积呈负相关(p=0.006,r=-0.39)。
结论:局部全细胞冷冻保存和中央 EPC 分析是可能的。 高剂量(30 000 U)EPO可能在48C72小时动员EPC。 基线 EPC 水平与梗塞面积呈负相关,表明急性 EPC 动员可能是最大程度减少急性损伤的可行策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edward Lakatta其他文献
Edward Lakatta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edward Lakatta', 18)}}的其他基金
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
用于治疗应用的高级糖基化终产物的可溶性受体
- 批准号:
8552494 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
EPO 及其衍生物降低血压的治疗潜力
- 批准号:
9147229 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
Effects Of Age And Conditioning Status On Rest And Exercise Cardiac Performance
年龄和体能状态对休息和运动心脏功能的影响
- 批准号:
8931601 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
Matching ATP supply and demand in cardiac pacemaker cells
匹配心脏起搏细胞中的 ATP 供应和需求
- 批准号:
8931611 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
PDE3, PDE4 and PKC regulate local Ca2+ releases and cardiac pacemaker firing
PDE3、PDE4 和 PKC 调节局部 Ca2 释放和心脏起搏器放电
- 批准号:
8736511 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
Age-Associated Changes in Arterial Proteome and Aortic Smooth Muscle Signaling
动脉蛋白质组和主动脉平滑肌信号与年龄相关的变化
- 批准号:
8931487 - 财政年份:
- 资助金额:
$ 4.99万 - 项目类别:
相似海外基金
Non-invasive coronary thrombus imaging to define the cause of acute myocardial infarction
无创冠状动脉血栓显像可明确急性心肌梗塞的病因
- 批准号:
MR/Y009770/1 - 财政年份:2023
- 资助金额:
$ 4.99万 - 项目类别:
Fellowship
Impact of COVID-19 pandemic on pathophysiology of acute myocardial infarction and emergency cardiovascular care system
COVID-19大流行对急性心肌梗死病理生理学和心血管急诊系统的影响
- 批准号:
23K15160 - 财政年份:2023
- 资助金额:
$ 4.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Extreme Heat and Acute Myocardial Infarction: Effect Modifications by Sex, Medical History, and Air Pollution
酷热和急性心肌梗塞:性别、病史和空气污染的影响
- 批准号:
10709134 - 财政年份:2023
- 资助金额:
$ 4.99万 - 项目类别:
Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction
开发血液中的多 RNA 特征以进行快速诊断测试,以强有力地区分急性心肌梗死患者
- 批准号:
10603548 - 财政年份:2023
- 资助金额:
$ 4.99万 - 项目类别:
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10576349 - 财政年份:2022
- 资助金额:
$ 4.99万 - 项目类别:
Establishment of the emergency transport decision making program for patients with acute myocardial infarction using artificial intelligence (AI)
利用人工智能(AI)建立急性心肌梗死患者紧急转运决策方案
- 批准号:
22K09185 - 财政年份:2022
- 资助金额:
$ 4.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of effect of intracoronary supersaturated oxygen therapy on inhibition of no reflow phenomenon in acute myocardial infarction
冠状动脉内过饱和氧治疗抑制急性心肌梗死无复流现象的效果评价
- 批准号:
22K08135 - 财政年份:2022
- 资助金额:
$ 4.99万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Developing Federated Learning Strategies for Disease Surveillance Using Cross-Jurisdiction Electronic Medical Records without Data Sharing: With Applications to Acute Myocardial Infarction, Hypertension, and Sepsis Detection
使用跨辖区电子病历(无需数据共享)开发疾病监测联合学习策略:在急性心肌梗塞、高血压和脓毒症检测中的应用
- 批准号:
468573 - 财政年份:2022
- 资助金额:
$ 4.99万 - 项目类别:
Operating Grants
Effectiveness of Strategies to Improve Outcomes after Hospitalization for Acute Myocardial Infarction in Older Adults
改善老年人急性心肌梗死住院后预后的策略的有效性
- 批准号:
10339915 - 财政年份:2022
- 资助金额:
$ 4.99万 - 项目类别:
The Personalising Acute Myocardial Infarction Care to improve Outcomes (PAMICO Project)
个性化急性心肌梗死护理以改善结果(PAMICO 项目)
- 批准号:
nhmrc : 2005797 - 财政年份:2021
- 资助金额:
$ 4.99万 - 项目类别:
Partnership Projects